Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1532 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Ji Hye Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Metformin, Fasting, Uracil, Food-Drug Interactions. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
This phase 1, randomized, open‐label, 2 × 2 crossover study evaluated the bioequivalence of fixed‐dose combination (FDC) formulations of alogliptin (ALO) and metformin extended‐release (MET XR) compared to their individual formulations and assessed the effect of food on FDC pharmacokinetics in healthy participants. The study comprised the high‐dose bioequivalence study (ALO 25 mg/MET XR 1000 mg) and the low‐dose bioequivalence study (ALO 12.5 mg/MET XR 500 mg), both conducted under fasting conditions, and the food effect study (ALO 12.5 mg/MET XR 1000 mg) conducted under both fasting and fed conditions. Among enrolled participants, 46 of 50 completed the high‐dose bioequivalence study, 45 of 51 completed the low‐dose bioequivalence study, and 22 of 26 completed the food effect study. Plasma concentrations were analyzed using liquid chromatography‐tandem mass spectrometry. The geometric mean ratios of AUC last and C max for the FDC versus individual formulations were within the bioequivalence range (0.80‐1.25) for both ALO and MET XR. ALO's pharmacokinetics were unaffected by food, while MET XR exhibited a significant food effect, with AUC last increasing by a factor of 1.63 and T max delayed by 2 hours. Given these findings, the FDC should be administered with food, consistent with MET XR monotherapy recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Global Clinical Development Department, Celltrion Inc., Incheon, Republic of Korea.
Zitieren
APA
Song, J. H., Kim, J. H., Hong, J. H., Jung, J. G., Park, S. Y., & Sunwoo, J. (2025). Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1532
Vancouver
Song JH, Kim JH, Hong JH, Jung JG, Park SY, Sunwoo J. Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1532
BibTeX
@article{Song2025,
author = {Song, Ji Hye and Kim, Jae Hoon and Hong, Jang Hee and Jung, Jin-Gyu and Park, Sun Young and Sunwoo, Jung},
title = {Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1532}
}
EUVIMED